Compare Citius Pharmaceuticals Inc (CTXR) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Riot Platforms Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Riot Platforms Inc trades at $19.84 (market cap $7.64B). The key difference: Riot Platforms Inc is far larger — about 521.9× Citius Pharmaceuticals Inc's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | RIOT | |
|---|---|---|
Market Cap | $14.64M | $7.64B |
Sector | Health | Technology |
52-Week High | $1.82 | $28.67 |
52-Week Low | $0.53 | $11.03 |
Enterprise Value | $10.86M | $8.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
RIOT stock trades at $20.19, down 3.7% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $663.18 million in 2025, with a negative net income margin of -132.76%, though revenue reached $647.44 million. Analyst consensus remains strongly bullish with a $27.86 price target, supported by 17 buy ratings. Recent news highlights volatility amid broader crypto stock trends and a strategic pivot toward high-performance computing.
The outlook is mixed: strong analyst support and a strategic shift to data centers offer upside, but persistent losses, negative cash flow from operations, and sensitivity to Bitcoin market swings pose significant risks. Investors should weigh the high valuation multiples against the company's unprofitability and execution challenges in its expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
